Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women

Polish Journal of Pathology

Volumn 63, Issue 4, 2012, Pages 278-283

  Zajac, Agnieszka ^a   Stachowiak, Grzegorz ^a   Pertyński, Tomasz ^a   Romanowicz, Hanna ^a   Wilczyński, Jacek ^a   Smolarz, Beata ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Endometrial cancer; Gene polymorphism; MDM2

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2;

AGED; ARTICLE; ENDOMETRIUM TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MIDDLE AGED; POLAND; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLAND; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RISK FACTORS;

EID: 84873843794     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: 10.5114/PJP.2012.32776     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Wojciechowska U, Didkowska J, Zatoński W. Corpus uteri cancer. In: Zatoński W (ed.). Cancer in Poland in 2006. Department of Epidemiology and Cancer Prevention. Warszawa 2008; 30-32.
3. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
4. Martin K, Trouche D, Hagemeier C, et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691-694.
5. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-698.
6. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycleinhibitory function induces tumorigenesis. EMBO J 1998; 17: 2513-2525.
7. Nayak MS, Yang JM, Hait WN. Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res 2007; 67: 5831-5839.
8. Soslow RA, Shen PU, Chung MH, Isacson C. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998; 17: 129-134.
9. Stewart RL, Royds JA, Burton JL, et al. Direct sequencing of the p53 gene shows absence of mutations in endometrioid endometrial adenocarcinomas expressing p53 protein. Histopathology 1998; 33: 440-445.
10. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
11. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 2006; 66: 5104-5110.
12. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006; 43: 531-533.
13. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006; 98: 285-288.
14. Hu Z, Jin G, Wang L, et al. MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev 2007; 16: 2717-2723.
15. Terry K, McGrath M, Lee IM, et al. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 983-986.
16. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006; 24: 4434-4440.
17. Dharel N, Kato N, Muroyama R, et al. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res 2006; 12: 4867-4871.
18. Lind H, Zienolddiny S, Ekstrøm PO, et al. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006; 119: 718-721.
19. Walsh CS, Miller CW, Karlan BY, Koeffler HP. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk. Gynecol Oncol 2007; 104: 660-664.
20. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
21. Onat OE, Tez M, Ozçelik T, Törüner GA. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res 2006; 26: 3473-3475.
22. Ma H, Hu Z, Zhai X, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006; 240: 261-267.
23. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006; 240: 195-197.
24. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 2005; 42: 694-698.
25. El Hallani S, Marie Y, Idbaih A, et al. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J Neurooncol 2007; 85: 241-244.
26. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis 2007; 28: 2262-2267.
27. Ashton KA, Proietto A, Otton G, et al. Polymorphisms in TP53 and MDM2 combined are associated with high grade endometrial cancer. Gynecol Oncol 2009; 113: 109-114.
28. Nunobiki O, Ueda M, Yamamoto M, et al. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer. Hum Cell 2009; 22: 101-106.
29. Ueda M, Yamamoto M, Nunobiki O, et al. Murine doubleminute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer. Hum Cell 2009; 22: 49-54.